|
| General Information |
| Business: |
We are an endocrine-focused biopharmaceutical company initially developing our novel long-acting recombinant human growth hormone, VRS-317, for growth hormone deficiency, or GHD, an orphan disease. A key limitation to current recombinant human growth hormone, or rhGH, products is that they impose the burden of daily injections over multiple years, often resulting in poor compliance, which in turn can lead to suboptimal treatment outcomes in GHD patients. Despite this limitation, global annual sales from currently marketed rhGH products have grown approximately 6% per year over the last five years, reaching over $3 billion in 2012. Based on market research, we believe that the market for daily rhGH products is likely to grow to over $4 billion by 2018. VRS-317 is intended to reduce the burden of daily treatment by requiring significantly fewer injections, potentially improving compliance and, therefore, treatment outcomes. |
|
| Industry: |
PHARMACEUTICAL PREPARATIONS |
|
| Employees: |
14 |
Founded: |
2008 |
|
| Contact Information |
| Address: |
275 Shoreline Drive, Suite 450, Redwood City, CA 94065, US |
|
|
|
|
|
|
|
| Financial Information |
| |
| Revenues: |
$ 0.0 mil (last 12 months) |
|
| Net Income: |
$ -18.5 mil (last 12 months) |
|
| IPO Profile |
|
|
|
|
